Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Conditions

Myasthenia Gravis 3

Interventions

rozanolixizumab 5zilucoplan 4eculizumab 4efgartigimod alfa 3Rituximab 2Prednisone 2Amifampridine 2thymoglobulin 1satralizumab 1rhoA GTP-Binding Protein 1ravulizumab 1iscalimab 1inebilizumab 1gamma-Globulins 1Thymectomy 1Sugars 1Steroids 1Sodium Chloride 1Robotic Surgical Procedures 1Prednisolone 1Methylprednisolone 1Methotrexate 1Mesna 1Hizentra 1Hematopoietic Stem Cell Transplantation 1Granulocyte Colony-Stimulating Factor 1Fluid Therapy 1Cyclophosphamide 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Myasthenia Gravis × efgartigimod alfa × Clear all
NCT02965573 2024-08-28

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

argenx

Phase 2 Completed
24 enrolled 28 charts

Myasthenia Gravis

NCT03770403 2023-07-14

ADAPT+

argenx

Phase 3 Completed
151 enrolled 11 charts

Myasthenia Gravis

NCT03669588 2022-02-08

ADAPT

argenx

Phase 3 Completed
167 enrolled 18 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡